Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach

作者：Rotolo F^*; Dunant A; Le Chevalier T; Pignon J P; Arriagada R

来源：Annals of Oncology, 2014, 25(11): 2162-2166.

DOI：10.1093/annonc/mdu442

• cisplatin
• nonsmall-cell lung cancer
• adjuvant chemotherapy
• randomized trial
• multistate model
• failure pattern

Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer (NSCLC) reduces the risk of local relapse and of nonbrain metastasis, improving survival. It has no residual effect on mortality in the first 5 years, but is associated to a higher risk of noncancer mortality thereafter. Detailed longterm follow-up is strongly recommended in randomized trials evaluating adjuvant treatments in NSCLC.Adjuvant cisplatin-based chemotherapy has become the standard therapy against resected nonsmall-cell lung cancer (NSCLC). Because of variable results on its late effect, we reanalyze the long-term data of the International Adjuvant Lung Cancer Trial (IALT) to describe in details the role of adjuvant chemotherapy.
In the IALT, 1867 patients were randomized between adjuvant cisplatin-based chemotherapy and control, who were followed up for a median of 7.5 years. Of these, 1687 patients were enrolled from 132 centers accepting to report the times to cancer events. We used event history methodology to estimate the effects of adjuvant chemotherapy on the risks of local relapse, distant metastasis, and death.
Adjuvant chemotherapy was highly effective against local relapses [HR = 0.73; 95% confidence interval (CI) 0.60-0.90; P = 0.003] and nonbrain metastases (HR = 0.79; 95% CI 0.66-0.94; P = 0.008) but not against brain metastases (HR = 1.1; 95% CI 0.82-1.4; P = 0.61). The effect on noncancer mortality was nonsignificant during the first 5 years (HR = 1.1; 95% CI 0.81-1.5; P = 0.29), whereas the risk of noncancer mortality was subsequently higher with treatment (HR = 3.6; 95% CI 2.2-5.9; P < 0.001). This harmful effect, however, potentially concerned only about 2% of the patients at 8 years.
Adjuvant cisplatin-based chemotherapy reduced the risk of local relapse and of nonbrain metastasis, thereby improving survival. This treatment exerted no residual effect on mortality during the first 5 years, but a higher risk of noncancer mortality was found thereafter. Detailed long-term follow-up is strongly recommended for all patients in randomized trials evaluating adjuvant treatments in NSCLC.

• 出版日期2014-11